Targeted Botanical and Herbal Food and Drinks in Europe

  • EXECUTIVE SUMMARY
    • The product launch landscape
    • The health claims landscape
    • The clinical trials landscape
  • Introduction
    • What is the report about?
    • Methodology
    • Report structure
      • Tracing the origin of botanicals and herbs
      • The growing demand for functional food and drinks
      • Regulatory impact
  • The product launch landscape
    • Summary
    • Introduction
    • NPD by ingredient
      • Products with new ingredients
    • NPD by product category
    • Claims analysis
      • Metabolic disorders and endocrinology
      • Digestive health
      • Anti-infective
      • Cardiovascular system
      • Beauty from within
    • Conclusions
  • The health claims landscape
    • Summary
    • Introduction
    • European Union Nutrition and Health Claims Regulation
      • “General function” claims under Article 13.1
      • The Traditional Herbal Medicinal Products Directive
    • EFSA health claims analysis
      • EFSA’s opinion on submitted health claims
      • Targeted therapeutic areas by health claims submission
    • Conclusions
  • The clinical trials landscape
    • Summary
    • Introduction
    • Existing clinical evidence for botanicals and herbs
      • Establishing a cause and effect relationship
      • Assessing clinical trials by therapeutic area
    • Conclusions
  • Conclusions
    • The impact of more stringent regulations
      • The convergence of food and pharma
      • Increased R&D investment
      • Developing products without a health claim
    • Assessment of research, manufacturing and health claim activities
      • Key botanicals
      • Current market landscape summary
      • Key targeted therapeutic areas
    • Conclusions
  • TABLES
    • Table: Botanicals and herbs covered in the report
    • Table: Functional food and drinks sales ($m), 2002-2012
    • Table: Botanicals and herbs used in food and drinks (%), 2007–10
    • Table: Targeted therapeutic areas by health claims on new product launches (%), 2007–10
    • Table: Prevalence of obesity (BMI at least 30 kg/m²) in adults across the seven major markets (%), 2010
    • Table: Prevalence of diabetes mellitus across the seven major markets (000s), 2008
    • Table: Prevalence of IBS across seven major markets (‘000s), 2008
    • Table: Prevalence of OA across seven major markets (‘000s), 2007
    • Table: Estimated prevalence of dyslipidemia across the seven major markets (‘000s), 2009
    • Table: Estimated prevalence of hypertension across the seven major markets (‘000s), 2009
    • Table: Oral beauty supplements market value, US & Europe ($m), 2001-2011
    • Table: EFSA negative opinions for botanicals health claims, 2010
    • Table: Targeted therapeutic areas by health claims submitted to EFSA, 2007-10
    • Table: Botanicals and herbs status by clinical trials, 2007–10
    • Table: Targeted health areas of clinical trials, 2007–10
    • Table: Future opportunities in botanicals and herbs as indicated by successful clinical testing
  • FIGURES
    • Figure: Venom Energy – Black Mamba
    • Figure: Boresha NuvoGene Tea - Patented Thermogenic Low-Glycemic Fat-Burning Energy Drink - Tropical Fruit Flavor
    • Figure: Breyers YoCrunch – 100 Calorie Pack
    • Figure: Fanta Still
    • Figure: SteazEnergy – Organic Fuel
    • Figure: New product launches by industry and category (%), 2010
    • Figure: Neo Beauty - Probiotic Drink - Aloe Vera
    • Figure: Targeted therapeutic areas by health claims on new product launches (%), 2007 and 2010
    • Figure: Drivers of application of botanicals in food and drinks for dermatological benefits
    • Figure: Borba - Balance Gummi Bears
    • Figure: Danone Essensis
    • Figure: Legal framework for botanicals market under food laws in EU
    • Figure: Herbs and botanicals with THR certification from MHRA
    • Figure: Classification of herbs and botanicals by number of health claims submitted to EFSA, 2007–10
    • Figure: Botanicals and herbs compared by the number of health claim submissions to EFSA and overall R&D activity, 2007–10
    • Figure: EFSA’s opinion on submitted health claims for herbs and botanicals, 2007–10
    • Figure: Targeted therapeutic areas by health claim submissions, as of August 2010
    • Figure: Botanicals and herbs to be supported by clinical trials data (%), 2007–10
    • Figure: Targeted therapeutic areas of clinical trials (%), 2007–10
    • Figure: The impact of the EFSA regulations
    • Figure: Future of botanicals and herbs as indicated by research, manufacturing and health claim activities
    • Figure: Botanicals and herbs compared by the number of health claim submissions to EFSA and effective clinical trials, 2007–10
    • Figure: Botanicals by level of manufacturer interest and degree of clinical data support
    • Figure: Key targeted therapeutic areas by botanicals and herbs, 2007–10

Report

Published by
Business Insights
Published on
01 Jan 2011
Product code
BI00011-018
Pages
Please wait...

$2875

Multi-user License $10781